EC-18 has a mechanism to remove Covid-19 pathogens. Credit: CDC on Unsplash.

Enzychem Lifesciences is set to advance a domestic clinical trial of potential coronavirus (Covid-19) treatment candidate EC-18 in South Korea.

EC-18 has a mechanism to remove pathogens or viruses by enabling immune cells to engulf the virus or bacteria and remove them in a short period of time. It eliminates pathogens by capturing the virus or bacteria and binding it to the receptor.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Furthermore, EC-18 is capable of reducing the gathering of inflammatory cells due to rapid removal of damage associated molecular pattern (DAMPs) that accumulate when cells are damaged by radiation.

It also prevents tissue damage produced by the sudden activity inflammatory cells.

The compound is derived from Sika deer antler and contributes to the swift removal of PAMPs/DAMPs.

Enzychem is in talks with the relevant US Government authorities for development collaboration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Enzychem Lifesciences chairman and CEO Ki Young Sohn said: “EC-18 has a mechanism of action with a unique anti-Covid-19 that can swiftly remove it from cells, and we expect that EC-18 may become a strong countermeasure for Covid-19, which is currently evolving as global pandemic.”

Earlier this month, Enzychem applied to the Biomedical Advanced Research and Development Authority (BARDA) Medical Counter Measure (MCM) Covid-19 programme.

It is also advancing research collaboration with various government authorities and research institutes of China and Korea for the development of EC-18 as a potential therapy for the virus.

Coronavirus, which originated in China, has become a global pandemic, affecting more than half of countries worldwide.